Coherus Oncology (CHRS) Treasury Shares (2013 - 2025)
Coherus Oncology (CHRS) posted Treasury Shares of $188557.0 for Q4 2025, down 75.46% sequentially from $768237.0 in Q4 2024, and down 75.46% YoY from $768237.0 in Q4 2024.
Coherus Oncology (CHRS) Treasury Shares (2013 - 2025) Analysis & Trends
Coherus Oncology has reported Treasury Shares for 11 years, with the latest figure at $188557.0 in Q4 2025.
- Quarterly Treasury Shares fell 75.46% year-over-year to $188557.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $188557.0 (down 75.46% YoY) and the FY2025 annual result came in at $188557.0, down 75.46% from the prior year.
- Treasury Shares declined to $188557.0 in Q4 2025 per CHRS's latest filing, from $768237.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $2.3 million in Q4 2022 and troughed at $188557.0 in Q4 2025.
- A 5-year average of $1.4 million and a median of $1.7 million in 2023 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2021 and 2025: Treasury Shares soared 82.61% in 2021, then slumped 75.46% in 2025.
- Over 5 years, Treasury Shares stood at $1.8 million in 2021, then gained by 26.55% to $2.3 million in 2022, then retreated by 26.0% to $1.7 million in 2023, then sank by 55.51% to $768237.0 in 2024, then plunged by 75.46% to $188557.0 in 2025.
- According to Business Quant data, Treasury Shares over the past three periods registered $188557.0, $768237.0, and $1.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 188,557.00 |
| Dec 31, 2025 | 188,557.00 |
| Dec 31, 2024 | 768,237.00 |
| Dec 31, 2024 | 768,237.00 |
| Dec 31, 2023 | 1.73 Mn |
| Dec 31, 2023 | 1.73 Mn |
| Dec 31, 2022 | 2.33 Mn |
| Dec 31, 2022 | 2.33 Mn |
| Dec 31, 2021 | 1.84 Mn |
| Dec 31, 2021 | 1.84 Mn |
| Dec 31, 2020 | 1.01 Mn |
| Dec 31, 2020 | 1.01 Mn |
| Dec 31, 2019 | 104,750.00 |
| Dec 31, 2019 | 104,750.00 |
| Dec 31, 2018 | 44,387.00 |
| Dec 31, 2018 | 44,387.00 |
| Dec 31, 2017 | 120,377.00 |
| Dec 31, 2017 | 120,377.00 |
| Sep 30, 2014 | 21.13 Mn |
| Sep 30, 2014 | 21.13 Mn |